LAPORTE KATHLEEN 4

What Happened
Kathleen LaPorte, a director of Q32 Bio, was granted stock options covering 23,272 shares with an exercise price of $2.75 per share (aggregate reported value ≈ $63,998) on 2026-01-15. This was an award of options (a compensation grant), not an open-market purchase or sale — LaPorte did not buy or sell underlying shares at grant.

Key Details

• Transaction date: 2026-01-15; Grant type: award/option (derivative) at $2.75 per share.
• Reported aggregate value: $63,998.
• Vesting: Option vests in four equal quarterly installments on the last day of each calendar quarter, subject to continued service.
• Reason/compensation: Elected in lieu of cash retainer fees under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.
• Filing timeliness: The Form 4 notes the award was initially not reported due to administrative oversight; the Form 4 was filed 2026-01-30 covering the 2026-01-15 grant (late reporting).

Context
This was a grant of options (a compensation award) rather than an immediate purchase or sale of stock. The options must vest over upcoming quarters before they can be exercised; the filing does not indicate any immediate exercise or sale. Late reporting delays public visibility into insider compensation but does not by itself imply trading intent.